NeurologyLive Friday 5 — January 29, 2021

January 29, 2021
NeurologyLive Staff

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending January 29, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Inclusion Criteria for Multiple Sclerosis Trials Don’t Reflect Real-World Patients

Relapse, followed by medication history and age, was among the highest exclusion rates for MS trials across different disease-modifying therapies.

2: Mind Moments Episode 28: The Multiple Sclerosis Patient Journey

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive conversation between an expert neurologist, psychologist, patient, and care partner on various facets of multiple sclerosis.

3: Improving Outcomes in Patients With Early Onset NMOSD: Gabrielle Macaron, MD

The neurologist from Cleveland Clinic discussed how her team found that patients with AO ≤21 years old had worse visual outcomes than those >21 years old.

4: NeuroVoices: James Berry, MD, MPH, on Answer ALS’s Expanded Data Campaign

The director of the Massachusetts General Hospital ALS Care Center sat down to discuss "The Data is Here" campaign from Answer ALS, the world’s largest open-sourced ALS data portal.

5: Phase 4 RESPOND Trial and the Need for Similar Trials in SMA: Julie Parsons, MD

The primary investigator of RESPOND discussed the trial’s goals and measures, as well as insight into why clinical trials like it are important in spinal muscular atrophy.